IBD Icons launched
American Idol star Casey Abrams is promoting understanding of crohn’s and Colitis as well as offering a fantatsic prize for the ‘IBD icon’ of the year. Read more here:
Remicade/Infliximab has been FDA Approved for use in children. The FDA advisory panel has recommended expanding the indication for infliximab (Remicade) to include treatment of ulcerative colitis in children. Infliximab, a tumor necrosis factor (TNF) inhibitor, is already approved to treat ulcerative colitis in adults and is also approved to treat Crohn’s disease in both adults and children. Read more here: http://www.medpagetoday.com/Gastroenterology/InflammatoryBowelDisease/27679
Lonza wins contract for bertilimumab(how on earth do you pronounce that?!!!)
Lonza has won a contract to manufacture Immune Pharmaceuticals’ antibody-based drug for inflammatory disorders, bertilimumab, at its mammalian development and manufacturing facility in the UK.
The deal will see the Swiss CMO produce clinical supplies of the antibody in it’s centre in Milton Keynes. Bertilimumab is just about to start a phase II trials programme in inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis.
Bertilimumab is the first monoclonal antibody to specifically neutralise human eotaxin-1, a chemokine associated with inflammatory disease activity.
Read more here:http://www.inpharm.com/news/162751/lonza-antibody-contract-immune-pharmaceuticals-bertilimumab
Posted in News round up, Pharma
Tagged 2011, 31st, a, and, crohn's, health, July, las, news, Pharma, round, to, trip, up, Vegas, win, worklifespirit
A new report by visiongain, a London-based business information company, predicts that world drug revenues for treating inflammatory bowel diseases will reach $6.9bn in 2015, according to Inflammatory Bowel Diseases: World Drug Market 2011-2021, published in July 2011.
Diya Lahiri, pharmaceutical industry analyst, is quoted as saying: “The world IBD treatments market will benefit from the entry of new technologies, products and companies this decade. There are prominent needs in the IBD treatment market, the most important being the development of drugs that are disease modifying rather than only symptom managing. R&D efforts will help develop novel treatments that will not only benefit patients but also help researchers better understand IBD.”
Visiongain forecasts that the IBD drug market will continue to expand steadily to 2021. The future of the market appears promising, with
- increasing demand for IBD treatments
- a strong R&D pipeline for treating inflammatory bowel diseases
- the prospect of new, more-effective drugs, including biologics and intestinal anti-inflammatory agents (IAIs)
It’s all good news that our diseases are being invested in – and new effective treatments can’t come too soon for some of us.
For more information about this report please go here.